Metabolic and immunomodulatory control of type 2 diabetes via generating cellular itaconate reservoirs by inflammatory-targeting gene-therapy nanovesicles
Trends in Biotechnology · 2026-01 · 44 (1) · 170-192
DOI: 10.1016/j.tibtech.2025.07.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Biotechnology, 2026-01. Verfasst von An Lao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Cranio-maxillofacial Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of S…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Genetic Therapy, Succinates. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: School of Medicine, Shanghai Jiao Tong University, National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes (T2D) is characterized by persistent and unresolved tissue inflammation caused by the infiltration and dysregulation of immune cells. Current therapeutics targeting inflammatory immune cells for T2D remain limited. In this study, we analyzed single cell RNA from metabolic organs in T2D, revealing increased macrophage accumulation and a pathogenic macrophage subpopulation defined as NOD-like receptor (NLR) family pyrin domain-containing 3 (NLRP3)+ inflammatory and metabolically activated macrophages. To target these inflammatory cells, we developed nanovesicles encapsulating mitochondrial metabolic enzyme-related gene segments [immune-responsive gene 1 (IRG1)-overexpression plasmids] with cell membrane decoration. The nanovesicles functioned as cellular itaconate producers that elegantly circumvented the drug utilization barriers of a classic NLRP3 inhibitor and, as a mitochondria-reprograming system, mitigated fatty acid (FA)-associated metabolic dysfunction. The nanovesicles reversed inflammation, restored metabolic functions, and ameliorated obesity. Therefore, the metabolic and immunomodulatory functions of nanovesicles may offer translational opportunities for the prevention and treatment of T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Cranio-maxillofacial Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for Stomato…
- Department of Stomatology, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
- Department of Orthopedics, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201301, China. Electronic address: lidejian880820@163.com.
- Department of Obstetrics, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 201204, China. Electronic address: maarly@163.com.
Förderung
- School of Medicine, Shanghai Jiao Tong University
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Lao, A., Li, W., Sun, Y., Cao, Y., Zhuang, Y., Wu, J., Li, D., Lin, K., Mao, J., & Liu, J. (2026). Metabolic and immunomodulatory control of type 2 diabetes via generating cellular itaconate reservoirs by inflammatory-targeting gene-therapy nanovesicles. Trends in Biotechnology, 44(1), 170-192. https://doi.org/10.1016/j.tibtech.2025.07.025
Vancouver
Lao A, Li W, Sun Y, Cao Y, Zhuang Y, Wu J, et al. Metabolic and immunomodulatory control of type 2 diabetes via generating cellular itaconate reservoirs by inflammatory-targeting gene-therapy nanovesicles. Trends in Biotechnology. 2026;44(1):170-192. doi:10.1016/j.tibtech.2025.07.025
BibTeX
@article{Lao2026,
author = {Lao, An and Li, Weiqi and Sun, Yiting and Cao, Yuting and Zhuang, Yu and Wu, Jianyong and Li, Dejian and Lin, Kaili and Mao, Jing and Liu, Jiaqiang},
title = {Metabolic and immunomodulatory control of type 2 diabetes via generating cellular itaconate reservoirs by inflammatory-targeting gene-therapy nanovesicles},
journal = {Trends in Biotechnology},
year = {2026},
volume = {44},
number = {1},
pages = {170--192},
doi = {10.1016/j.tibtech.2025.07.025}
}
EUVIMED